Revolution Medicines, Inc. RVMD
We take great care to ensure that the data presented and summarized in this overview for Revolution Medicines, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RVMD
View all-
Vanguard Group Inc Valley Forge, PA17.1MShares$639 Million0.01% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$501 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA13.2MShares$495 Million3.09% of portfolio
-
Janus Henderson Group PLC London, X09.48MShares$354 Million0.22% of portfolio
-
Baker Bros. Advisors LP New York, NY7.94MShares$296 Million3.85% of portfolio
-
Nextech Invest Ag7.6MShares$284 Million61.97% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.55MShares$245 Million10.94% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$219 Million0.03% of portfolio
-
State Street Corp Boston, MA5.79MShares$216 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.39MShares$164 Million3.82% of portfolio
Latest Institutional Activity in RVMD
Top Purchases
Top Sells
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Insider Transactions at RVMD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 20
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
2,041
-3.42%
|
$77,558
$38.71 P/Share
|
Mar 17
2025
|
Xiaolin Wang |
SELL
Bona fide gift
|
Direct |
2,718
-2.59%
|
-
|
Mar 17
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
3,294
-1.11%
|
$128,466
$39.04 P/Share
|
Mar 17
2025
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,058
-1.95%
|
$119,262
$39.04 P/Share
|
Mar 17
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,864
-1.59%
|
$72,696
$39.04 P/Share
|
Mar 17
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
11,738
-2.59%
|
$457,782
$39.04 P/Share
|
Mar 17
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,458
-2.38%
|
$56,862
$39.04 P/Share
|
Mar 01
2025
|
Mark A Goldsmith |
BUY
Grant, award, or other acquisition
|
Direct |
97,400
+17.69%
|
-
|
Mar 01
2025
|
Xiaolin Wang |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+15.32%
|
-
|
Mar 01
2025
|
Lin Wei Chief Medical Officer |
SELL
Grant, award, or other acquisition
|
Direct |
20,800
-18.5%
|
-
|
Mar 01
2025
|
Margaret A Horn Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,600
+15.44%
|
-
|
Mar 01
2025
|
Stephen Michael Kelsey |
BUY
Grant, award, or other acquisition
|
Direct |
36,600
+10.99%
|
-
|
Mar 01
2025
|
Jack Anders Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,400
+14.86%
|
-
|
Mar 01
2025
|
Jeff Cislini General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+26.44%
|
-
|
Jan 21
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
2,406
-5.78%
|
$96,240
$40.5 P/Share
|
Dec 18
2024
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
30,846
+7.98%
|
$0
$0.49 P/Share
|
Dec 16
2024
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,329
-3.27%
|
$194,805
$45.4 P/Share
|
Dec 16
2024
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,635
-2.66%
|
$118,575
$45.4 P/Share
|
Dec 16
2024
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,599
-3.7%
|
$71,955
$45.4 P/Share
|
Dec 16
2024
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
4,663
-1.76%
|
$209,835
$45.4 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 265K shares |
---|---|
Open market or private purchase | 1.3M shares |
Exercise of conversion of derivative security | 401K shares |
Open market or private sale | 489K shares |
---|---|
Bona fide gift | 2.72K shares |
Sale (or disposition) back to the issuer | 1.81K shares |
Grant, award, or other acquisition | 20.8K shares |